 Joining me on the call today are Sujal Shah, chief executive officer; Dr. Sujal will provide an update on recent progress and plans on the development program for seladelpar, as well as a brief summary of our financials before we open the call up for QA. Before we begin, Id like to remind everyone that statements made during this conference call, including the QA session, relating to CymaBays expected future performance, business prospects, events or plans, including clinical plans, regulatory approvals and anticipated time lines and data release dates and cash runway are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, actual outcomes and results are subject to risks and uncertainties and could differ materially from those forecast due to the impact of many factors. 